Ravi Viswanathan - Net Worth and Insider Trading
Ravi Viswanathan Net Worth
The estimated net worth of Ravi Viswanathan is at least $1.4 Billion dollars as of 2024-04-27. Ravi Viswanathan is the 10% Owner of Tesaro Inc and owns about 10,420,645 shares of Tesaro Inc (TSRO) stock worth over $781 Million. Ravi Viswanathan is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $188 Million. Ravi Viswanathan is also the 10% Owner of Ra Pharmaceuticals Inc and owns about 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $167 Million. Besides these, Ravi Viswanathan also holds Adaptimmune Therapeutics PLC (ADAP) , Ardelyx Inc (ARDX) , AVEO Pharmaceuticals Inc (AVEO) , Mersana Therapeutics Inc (MRSN) , Millennial Media Inc (MM) , Epizyme Inc (EPZM) , Surface Oncology Inc (SURF) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) . Details can be seen in Ravi Viswanathan's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ravi Viswanathan has not made any transactions after 2018-09-07 and currently still holds the listed stock(s).
Transaction Summary of Ravi Viswanathan
Ravi Viswanathan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ravi Viswanathan owns 39 companies in total, including PhaseBio Pharmaceuticals Inc (PHASQ) , Marker Therapeutics Inc (MRKR) , and Elastic NV (ESTC) among others .
Click here to see the complete history of Ravi Viswanathan’s form 4 insider trades.
Insider Ownership Summary of Ravi Viswanathan
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
PHASQ | PhaseBio Pharmaceuticals Inc | 2018-10-17 | 10 percent owner |
MRKR | Marker Therapeutics Inc | 2018-10-17 | 10 percent owner |
ESTC | Elastic NV | 2018-10-04 | 10 percent owner |
ADAP | Adaptimmune Therapeutics PLC | 2018-09-07 | 10 percent owner |
AVEO | AVEO Pharmaceuticals Inc | 2018-08-21 | 10 percent owner |
ARDX | Ardelyx Inc | 2016-07-18 | 10 percent owner |
MULE | MuleSoft Inc | 2018-05-01 | 10 percent owner |
SURF | Surface Oncology Inc | 2018-04-23 | 10 percent owner |
TCON | TRACON Pharmaceuticals Inc | 2018-03-27 | 10 percent owner |
CASC | Cascadian Therapeutics Inc | 2018-03-09 | 10 percent owner |
TSRO | Tesaro Inc | 2018-03-06 | 10 percent owner |
ABIO | ARCA biopharma Inc | 2018-02-26 | 10 percent owner |
RARX | Ra Pharmaceuticals Inc | 2018-02-16 | 10 percent owner |
APPN | Appian Corp | 2017-11-27 | 10 percent owner |
SYBX | Synlogic Inc | 2015-09-30 | 10 percent owner |
GNCAQ | Genocea Biosciences Inc | 2018-01-19 | 10 percent owner |
SBBP | Strongbridge Biopharma PLC | 2018-01-01 | 10 percent owner |
XFOR | X4 Pharmaceuticals Inc | 2017-11-20 | 10 percent owner |
CRCM | Care.com Inc | 2017-11-06 | 10 percent owner |
RYTM | Rhythm Pharmaceuticals Inc | 2017-10-10 | 10 percent owner |
RGLS | Regulus Therapeutics Inc | 2017-07-24 | 10 percent owner |
MRSN | Mersana Therapeutics Inc | 2017-07-03 | 10 percent owner |
AKAOQ | Achaogen Inc | 2016-12-19 | 10 percent owner |
ROKA | Sorrento Tech Inc | 2016-09-21 | 10 percent owner |
ILIU | Interleukin Genetics Inc | 2016-07-29 | 10 percent owner |
EPZM | Epizyme Inc | 2016-01-12 | 10 percent owner |
AVTX | Avalo Therapeutics Inc | 2015-10-14 | 10 percent owner |
CSBR | Champions Oncology Inc | 2015-03-11 | 10 percent owner |
BOX | Box Inc | 2015-01-22 | 10 percent owner |
CVT | Cvent Inc | 2014-11-25 | 10 percent owner |
DERM | Dermira Inc | 2014-10-08 | 10 percent owner |
LOXO | Loxo Oncology Inc | 2014-08-06 | 10 percent owner |
HIVE | Aerohive Networks Inc | 2014-04-02 | 10 percent owner |
GLYC | GlycoMimetics Inc | 2014-01-09 | 10 percent owner |
CLVSQ | Clovis Oncology Inc | 2011-11-21 | 10 percent owner |
WDAY | Workday Inc | 2012-10-11 | 10 percent owner |
MM | Millennial Media Inc | 2012-10-29 | 10 percent owner |
DUOL | Duolingo Inc | 2022-06-24 | 10 percent owner |
GGNNQ | Genocea Biosciences Inc | 2018-01-19 | 10 percent owner |
Ravi Viswanathan Latest Holdings Summary
Ravi Viswanathan currently owns a total of 17 stocks. Among these stocks, Ravi Viswanathan owns 10,420,645 shares of Tesaro Inc (TSRO) as of March 6, 2018, with a value of $781 Million and a weighting of 57.74%. Ravi Viswanathan owns 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $188 Million and a weighting of 13.89%. Ravi Viswanathan also owns 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) as of October 31, 2016, with a value of $167 Million and a weighting of 12.38%. The other 14 stocks Adaptimmune Therapeutics PLC (ADAP) , Ardelyx Inc (ARDX) , AVEO Pharmaceuticals Inc (AVEO) , Mersana Therapeutics Inc (MRSN) , Millennial Media Inc (MM) , Epizyme Inc (EPZM) , Surface Oncology Inc (SURF) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) have a combined weighting of 15.98% among all his current holdings.
Latest Holdings of Ravi Viswanathan
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TSRO | Tesaro Inc | 2018-03-06 | 10,420,645 | 74.96 | 781,131,549 |
RYTM | Rhythm Pharmaceuticals Inc | 2017-10-10 | 4,909,956 | 38.28 | 187,953,116 |
RARX | Ra Pharmaceuticals Inc | 2016-10-31 | 3,490,073 | 47.99 | 167,488,603 |
ADAP | Adaptimmune Therapeutics PLC | 2018-09-07 | 94,978,668 | 1.08 | 102,102,068 |
ARDX | Ardelyx Inc | 2016-07-18 | 5,331,039 | 6.42 | 34,225,270 |
AVEO | AVEO Pharmaceuticals Inc | 2018-08-21 | 1,869,804 | 15.00 | 28,047,060 |
MRSN | Mersana Therapeutics Inc | 2017-07-03 | 8,140,138 | 2.94 | 23,932,006 |
MM | Millennial Media Inc | 2012-10-29 | 8,196,614 | 1.75 | 14,344,075 |
EPZM | Epizyme Inc | 2016-01-12 | 6,260,851 | 1.47 | 9,203,451 |
SURF | Surface Oncology Inc | 2018-04-23 | 3,312,877 | 1.07 | 3,544,778 |
DERM | Dermira Inc | 2014-10-02 | 17,241 | 18.75 | 323,269 |
ILIU | Interleukin Genetics Inc | 2016-07-29 | 55,418,811 | 0.00 | 249,385 |
AKAOQ | Achaogen Inc | 2016-12-19 | 5,215,128 | 0.03 | 130,378 |
CLVSQ | Clovis Oncology Inc | 2011-11-21 | 3,419,671 | 0.02 | 51,295 |
TCON | TRACON Pharmaceuticals Inc | 2018-03-27 | 17,330 | 1.81 | 31,367 |
ABIO | ARCA biopharma Inc | 2018-02-26 | 0 | 3.58 | 0 |
APPN | Appian Corp | 2017-11-27 | 0 | 37.56 | 0 |
Holding Weightings of Ravi Viswanathan
Ravi Viswanathan Form 4 Trading Tracker
According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Tesaro Inc (TSRO) over the past 5 years. The most-recent trade in Tesaro Inc is the acquisition of 145,532 shares on March 6, 2018, which cost Ravi Viswanathan around $8 Million.
According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 550,000 shares on October 10, 2017, which cost Ravi Viswanathan around $9 Million.
According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 435 shares on October 31, 2016, which brought Ravi Viswanathan around $5,655.
More details on Ravi Viswanathan's insider transactions can be found in the Insider Trading History of Ravi Viswanathan table.Insider Trading History of Ravi Viswanathan
- 1
Ravi Viswanathan Trading Performance
GuruFocus tracks the stock performance after each of Ravi Viswanathan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ravi Viswanathan is 24.93%. GuruFocus also compares Ravi Viswanathan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ravi Viswanathan within 3 months outperforms 20 times out of 29 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ravi Viswanathan's insider trading performs compared to the benchmark.
Performance of Ravi Viswanathan
Average Return
0.38%
Outperforming Transactions
32%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 8.63 | 24.93 | 24.27 | 0.38 | -22.48 | -17.19 |
Relative Return to S&P 500(%) | 7.35 | 21.05 | 18.65 | -11.31 | -31.4 | -30 |
Ravi Viswanathan Ownership Network
Ownership Network List of Ravi Viswanathan
Ownership Network Relation of Ravi Viswanathan
Ravi Viswanathan Owned Company Details
What does PhaseBio Pharmaceuticals Inc do?
Who are the key executives at PhaseBio Pharmaceuticals Inc?
Ravi Viswanathan is the 10 percent owner of PhaseBio Pharmaceuticals Inc. Other key executives at PhaseBio Pharmaceuticals Inc include 10 percent owner New Enterprise Associates 13 Lp , VP & Human Resources Glen Burkhardt , and Chief Commercial Officer Jonathan Birchall .
PhaseBio Pharmaceuticals Inc (PHASQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
PhaseBio Pharmaceuticals Inc (PHASQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
PhaseBio Pharmaceuticals Inc Insider Transactions
Ravi Viswanathan Mailing Address
Above is the net worth, insider trading, and ownership report for Ravi Viswanathan. You might contact Ravi Viswanathan via mailing address: 1954 Greenspring Drive, Suite 600, Timonium Md 21093.